Rx 2018: A New Era of Specialty Drugs, Telehealth, Mobile Apps and Value, IQVIA Reports
Health Populi
MARCH 13, 2018
Specifically, $19 billion worth of biotech spending will find biosimilar competition starting in 2018 for the first time. We don’t know yet what form that will take, but there is some indication that Dr. Azar is has his sights on some form of prescription drug pricing program, perhaps beginning with Medicare Part B.
168 
Let's personalize your content